Trials / Completed
CompletedNCT06745531
A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
A Phase 3, Randomized, Placebo-controlled, Double-blind Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 101 (actual)
- Sponsor
- Taisho Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A phase 3, randomized, placebo-controlled, double-blind study of TS-172 in hyperphosphatemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TS-172 20~60 mg/day | oral administration of TS-172 20\~60 mg/day |
| DRUG | Placebo | oral administration of placebo |
Timeline
- Start date
- 2025-01-06
- Primary completion
- 2025-10-13
- Completion
- 2025-10-20
- First posted
- 2024-12-20
- Last updated
- 2025-11-17
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT06745531. Inclusion in this directory is not an endorsement.